ERBB2 and breast cancer: Another phase Ib/II trial evaluated the effects of Buparlisib combined with trastuzumab in trastuzumab-resistant tumors in patients with advanced HER2+ BC, observing evidence of clinical activity (2% CR and 8% partial responses) [144].